Advanced glycation end products (AGEs) have been implicated in the pathogenesis of most chronic diseases. Therefore, identification of treatments that can attenuate the effects of these compounds and prevent cardiometabolic complications is of extreme public health interest. Recently, body weight management interventions showed positive results on reducing serum AGE concentrations. Moreover, the soluble receptor for advanced glycation end products (sRAGE) is considered to be a novel biomarker to identify patients with obesity most likely to benefit from weight management interventions. This systematic review aimed to critically analyze papers evaluating the effects of weight loss on serum AGEs and its receptors in adults with excess body weight. MEDLINE, Cochrane, Scopus, and Lilacs databases were searched. Three studies evaluating the response of AGEs to energy-restricted diets and six assessing sRAGE as the primary outcome were included. Energy-restricted diets and bariatric surgery reduced serum AGE concentrations, but effects on endogenous secretory RAGE (esRAGE) and sRAGE concentrations are conflicting. These results may be associated with mechanisms related to changes in dietary intake and limiting endogenous AGE formation. Therefore, the role of energy-restricted diets and bariatric surgery on lowering serum AGE concentrations, as well as its effects on AGEs receptors, deserves further investigation. K E Y W O R D S advanced glycation end product, bariatric surgery, caloric restriction, overweight, sRAGE 1 | BACKGROUND Obesity prevalence has nearly tripled in the past decades, and it has reached epidemic proportions worldwide. According to the World Health Organization in 2016, 39% of the adult population had overweight, and 13% had obesity. 1 Being overweight is a significant risk factor for cardiovascular and metabolic diseases. 2,3 Furthermore, inflammation and oxidative stress are complications associated toAbbreviations: AGEs, advanced glycation end products; RAGE, receptor for advanced glycation end products; NF-kB, nuclear factor kappa B; sRAGE, soluble receptor advanced glycation end products; PRISMA, preferred reporting items for systematic reviews and meta-